Syner-Med Improves Sales Execution With Veeva OpenData
December 07 2017 - 7:03AM
Business Wire
Veeva delivers the right data and insights for
UK pharmaceutical company to drive tailored interactions with
customers
Veeva Systems today announced that Syner-Med (PP) Ltd., a
fast-growing U.K. pharmaceutical company, is using Veeva OpenData
and Veeva CRM to empower field teams with accurate customer data
and drive smarter engagement with customers. Veeva OpenData and
Veeva CRM are part of Veeva Commercial Cloud, a suite of
applications that Syner-Med is adopting to establish a foundation
for their commercial operations as the company launches more new
products over the next two years.
“Veeva delivers quality customer data, right in CRM, to improve
our sales execution and create more valued interactions with our
customers,” said Dipak Bhatti, managing director of Syner-Med. “We
now have the foundation in place for a consistent commercial
approach and to support our future growth.”
Syner-Med’s previous data sources limited their ability to track
customer activities and placed a heavy administrative burden on
field reps to maintain accurate customer data. Data change requests
could often take weeks, so sales and marketing teams worked from
outdated information and had a fragmented view of customer
engagement across the company.
Veeva brings together complete customer data and multichannel
engagement to help Syner-Med achieve greater commercial
effectiveness. Veeva OpenData keeps data current using a
combination of data science and Veeva data stewards that can make
change requests within two hours versus the industry average of 10
days or more. As a result, field teams have an accurate view of
their customers in Veeva CRM to deliver smarter, more informed
interactions.
“Quality customer data is key to successful commercial execution
and increased sales and marketing efficiency,” said Rebecca Silver,
global vice president of Veeva OpenData. “With accurate data in
Veeva CRM, Syner-Med field and medical teams can drive more
value-based conversations with their customers.”
Veeva OpenData delivers access to approximately 16 million
healthcare professionals (HCPs) and their healthcare organizations
(HCOs) spanning 42 countries. Veeva OpenData can help customers
achieve greater commercial success and improve sales execution and
customer engagement.
Looking ahead, Syner-Med plans to adopt additional Veeva
Commercial Cloud applications, including Veeva Vault PromoMats to
combine creation, review, and distribution of commercial content
with digital asset management; Veeva Align to perform fast,
accurate territory alignments; Veeva CRM Approved Email and Veeva
CRM Engage to extend reach through digital channels such as email,
online meetings, and virtual events; and Veeva CLM to tailor calls
and make sales materials easy to access and share.
Veeva Commercial Cloud is the life sciences industry’s trusted
foundation for intelligent customer engagement. To learn more about
how Veeva Commercial Cloud is helping life sciences companies place
their customers at the center of their commercial strategies, visit
veeva.com/CommercialCloud.
Additional Information
For more on Veeva OpenData, visit: veeva.com/OpenDataConnect
with Veeva on LinkedIn: linkedin.com/company/veeva-systemsFollow
@veevasystems on Twitter: twitter.com/veevasystemsLike Veeva on
Facebook: facebook.com/veevasystems
About Veeva Systems
Veeva Systems Inc. is a leader in cloud-based software for the
global life sciences industry. Committed to innovation, product
excellence, and customer success, Veeva has more than 600
customers, ranging from the world's largest pharmaceutical
companies to emerging biotechs. Veeva is headquartered in the San
Francisco Bay Area, with offices in Europe, Asia, and Latin
America. For more information, visit veeva.com.
Forward-looking Statements
This release contains forward-looking statements, including the
market demand for and acceptance of Veeva’s products and services,
the results from use of Veeva’s products and services, and general
business conditions, particularly in the life sciences industry.
Any forward-looking statements contained in this press release are
based upon Veeva’s historical performance and its current plans,
estimates, and expectations, and are not a representation that such
plans, estimates, or expectations will be achieved. These
forward-looking statements represent Veeva’s expectations as of the
date of this press announcement. Subsequent events may cause these
expectations to change, and Veeva disclaims any obligation to
update the forward-looking statements in the future. These
forward-looking statements are subject to known and unknown risks
and uncertainties that may cause actual results to differ
materially. Additional risks and uncertainties that could affect
Veeva’s financial results are included under the captions, “Risk
Factors” and “Management’s Discussion and Analysis of Financial
Condition and Results of Operations,” in the company’s filing on
Form 10-Q for the period ended October 31, 2017. This is available
on the company’s website at veeva.com under the Investors section
and on the SEC’s website at sec.gov. Further information on
potential risks that could affect actual results will be included
in other filings Veeva makes with the SEC from time to time.
® 2017 Veeva Systems Inc. All rights reserved. Veeva and the
Veeva logo are trademarks of Veeva Systems Inc.Veeva Systems Inc.
owns other registered and unregistered trademarks.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171207005394/en/
Veeva SystemsRoger Villareal,
925-264-8885roger.villareal@veeva.comorLisa Barbadora,
610-420-3413pr@veeva.com
Veeva Systems (NYSE:VEEV)
Historical Stock Chart
From Aug 2024 to Sep 2024
Veeva Systems (NYSE:VEEV)
Historical Stock Chart
From Sep 2023 to Sep 2024